Isoquercitrin
Based on 9 publication(s) in Google Scholar
Isoquercetin (Quercetin 3-glucoside) is a naturally occurring polyphenol that has antioxidant, anti-proliferative, and anti-inflammatory properties. Isoquercetin alleviates ethanol-induced hepatotoxicity, oxidative stress, and inflammatory responses via the Nrf2/ARE antioxidant signaling pathway. Isoquercetin regulates the expression of nitric oxide synthase 2 (NO2) via modulating the nuclear factor-κB (NF-κB) transcription regulation system. Isoquercetin has high bioavailability and low toxicity, is a promising candidate agent to prevent birth defects in diabetic pregnancies.
For research use only. We do not sell to patients.
- Purity : 99.64%
- CAS No.: 482-35-9
- Formula: C21H20O12
- Molecular Weight:464.38
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications Citing Use of MedChemExpress (MCE) Isoquercitrin
More- Nat Aging. 2024 Sep;4(9):1231-1248. [Abstract]
- Sci Adv. 2025 May 2;11(18):eadu6676. [Abstract]
- Phytother Res. 2025 Oct;39(10):4802-4820. [Abstract]
- Cell Rep. 2023 Nov 10;42(11):113417. [Abstract]
- Biochem Pharmacol. 2026 Oct:252:118212.
- Molecules. 2024 Oct 30;29(21):5130. [Abstract]
- J Sep Sci. 2026 Apr;49(4):e70402. [Abstract]
- Chem Biol Drug Des. 2024 Sep;104(3):e14620. [Abstract]
- Eur Rev Med Pharmacol Sci. 2025 Sep;29(9):425-433. [Abstract]
-
Cell Imaging/Staining
-
RT-PCR
-
WB
-
In Vivo Imaging
-
Cell Imaging/Staining
Biological Activity
Description
IC50 & Target
|
iNOS |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
>10 μM
Compound: 11
|
Cytotoxicity against human A549 cells after 48 hrs by SRB assay
Cytotoxicity against human A549 cells after 48 hrs by SRB assay
|
[PMID: 28165740] |
| B16-4A5 | IC50 |
>100 μM
Compound: 9
|
Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells after 72 hrs by microplate reader analysis
Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells after 72 hrs by microplate reader analysis
|
[PMID: 25987378] |
| BMDC | IC50 |
>50 μM
Compound: 15
|
Inhibition of LPS-induced IL-12 p40 production in wild-type C57BL/6 mouse BMDC pretreated with compound for 1 hr before LPS treatment measured 16 hrs by ELISA
Inhibition of LPS-induced IL-12 p40 production in wild-type C57BL/6 mouse BMDC pretreated with compound for 1 hr before LPS treatment measured 16 hrs by ELISA
|
[PMID: 25769817] |
| BMDC | IC50 |
>50 μM
Compound: 15
|
Inhibition of LPS-induced IL-6 production in wild-type C57BL/6 mouse BMDC pretreated with compound for 1 hr before LPS treatment measured 16 hrs by ELISA
Inhibition of LPS-induced IL-6 production in wild-type C57BL/6 mouse BMDC pretreated with compound for 1 hr before LPS treatment measured 16 hrs by ELISA
|
[PMID: 25769817] |
| BMDC | IC50 |
>50 μM
Compound: 15
|
Inhibition of LPS-induced TNF-alpha production in wild-type C57BL/6 mouse BMDC pretreated with compound for 1 hr before LPS treatment measured 16 hrs by ELISA
Inhibition of LPS-induced TNF-alpha production in wild-type C57BL/6 mouse BMDC pretreated with compound for 1 hr before LPS treatment measured 16 hrs by ELISA
|
[PMID: 25769817] |
| BT-549 | IC50 |
>10 μM
Compound: 11
|
Cytotoxicity against human BT549 cells after 48 hrs by SRB assay
Cytotoxicity against human BT549 cells after 48 hrs by SRB assay
|
[PMID: 28165740] |
| BV-2 | IC50 |
13.39 μM
Compound: 5
|
Antineuroinflammatory activity in human BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction
Antineuroinflammatory activity in human BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction
|
[PMID: 27623545] |
| BV-2 | IC50 |
19.8 μM
Compound: 18
|
Antineuroinflammatory activity against mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method
Antineuroinflammatory activity against mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method
|
[PMID: 23149227] |
| BV-2 | IC50 |
55.59 μM
Compound: 11
|
Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitrite production after 24 hrs by Griess assay
Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitrite production after 24 hrs by Griess assay
|
[PMID: 28165740] |
| HEK293 | IC50 |
33.6 μM
Compound: 15
|
Inhibition of TNF-alpha-induced NFkappaB activation in human HEK293 cells after 6 hrs by luciferase reporter gene assay
Inhibition of TNF-alpha-induced NFkappaB activation in human HEK293 cells after 6 hrs by luciferase reporter gene assay
|
[PMID: 21261296] |
| Jurkat | IC50 |
>100 μg/mL
Compound: 10
|
Cytotoxicity against human Jurkat T cells after 36 hrs by MTT assay
Cytotoxicity against human Jurkat T cells after 36 hrs by MTT assay
|
[PMID: 21546250] |
| KB | ED50 |
>100 μg/mL
Compound: NSC-407304
|
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
|
[PMID: 469554] |
| MDCK | CC50 |
>400 μg/mL
Compound: 5
|
Antiviral activity against influenza virus type A H1N1 in MDCK cells assessed as inhibition of virus-induced cytopathic effect
Antiviral activity against influenza virus type A H1N1 in MDCK cells assessed as inhibition of virus-induced cytopathic effect
|
[PMID: 15104496] |
| MDCK | CC50 |
>431 μM
Compound: Isoquercitrin
|
Cytotoxicity against MDCK cells
Cytotoxicity against MDCK cells
|
[PMID: 25096296] |
| MDCK | CC50 |
23.4 μg/mL
Compound: 5
|
Antiviral activity against PIV3 in MDCK cells assessed as inhibition of virus-induced cytopathic effect
Antiviral activity against PIV3 in MDCK cells assessed as inhibition of virus-induced cytopathic effect
|
[PMID: 15104496] |
| MDCK | ED50 |
1.2 μM
Compound: 2, Isoquercetin
|
Antiviral activity against influenza A virus (A/swine/OH/511445/2007(H1N1)) Oh7 infected in MDCK cells assessed as inhibition of viral replication after 4 days by quantitative RT-PCR
Antiviral activity against influenza A virus (A/swine/OH/511445/2007(H1N1)) Oh7 infected in MDCK cells assessed as inhibition of viral replication after 4 days by quantitative RT-PCR
|
[PMID: 22115591] |
| MDCK | IC50 |
>500 μg/mL
Compound: 5
|
Antiviral activity against influenza virus type A H1N1 in MDCK cells assessed as inhibition of virus-induced cytopathic effect
Antiviral activity against influenza virus type A H1N1 in MDCK cells assessed as inhibition of virus-induced cytopathic effect
|
[PMID: 15104496] |
| MDCK | IC50 |
23.4 μg/mL
Compound: 5
|
Antiviral activity against PIV3 in MDCK cells assessed as inhibition of virus-induced cytopathic effect
Antiviral activity against PIV3 in MDCK cells assessed as inhibition of virus-induced cytopathic effect
|
[PMID: 15104496] |
| MDCK | IC50 |
23.4 μg/mL
Compound: 5
|
Cytotoxicity against MDCK cells
Cytotoxicity against MDCK cells
|
[PMID: 15104496] |
| MDCK | IC50 |
5.9 μg/mL
Compound: 5
|
Antiviral activity against RSV Long in MDCK cells assessed as inhibition of virus-induced cytopathic effect
Antiviral activity against RSV Long in MDCK cells assessed as inhibition of virus-induced cytopathic effect
|
[PMID: 15104496] |
| N9 | IC50 |
75.2 μM
Compound: 15
|
Antineuroinflammatory activity in mouse N9 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay
Antineuroinflammatory activity in mouse N9 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay
|
[PMID: 28073678] |
| Raji | IC50 |
570 molar ratio
Compound: 14
|
Inhibition of TPA-induced EBV-early antigen activation in human Raji cells relative to TPA
Inhibition of TPA-induced EBV-early antigen activation in human Raji cells relative to TPA
|
[PMID: 17190444] |
| RAW264.7 | IC50 |
>50 μM
Compound: 17
|
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion after 18 hrs by sandwich ELISA
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion after 18 hrs by sandwich ELISA
|
[PMID: 24679441] |
| RAW264.7 | IC50 |
61.2 μM
Compound: 10
|
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method
|
[PMID: 21353543] |
| RAW264.7 | IC50 |
76.3 μM
Compound: 10
|
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion after 18 hrs
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion after 18 hrs
|
[PMID: 21353543] |
| SK-MEL-2 | IC50 |
>10 μM
Compound: 11
|
Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay
Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay
|
[PMID: 28165740] |
| SK-OV-3 | IC50 |
>10 μM
Compound: 11
|
Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay
Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay
|
[PMID: 28165740] |
In Vitro
Isoquercetin (Quercetin 3-glucoside; 5-20 μM; 24 hours) substantially reduces ethanol-induced cytotoxicity , protects hepatic cells against ethanol-stimulated liver injury[1]. Isoquercetin (10 μM; pre-treat 1 hour) dramatically downregulates the levels of ethanol-induced iNOS protein expression in HepG2 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HepG2 cells
-
Concentration:5 μM, 10 μM, 20 μM
-
Incubation Time:24 hours
-
Result:Caused significantly enhanced cell viability as positive controls.
-
Cell Line:HepG2 cells
-
Concentration:10 μM
-
Incubation Time:1 hour
-
Result:Decreased ethanol‐ induced iNOS protein expression.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 482-35-9
-
Appearance Solid
-
Molecular Weight 464.38
-
Formula C21H20O12
-
Color Light yellow to yellow
-
SMILES
O=C1C(O[C@H]2[C@@H]([C@H]([C@@H]([C@@H](CO)O2)O)O)O)=C(C3=CC=C(O)C(O)=C3)OC4=CC(O)=CC(O)=C14
-
Synonyms
Isoquercetin; Quercetin 3-glucoside
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (9)
-
Journal Impact Factor
-
Most Recent
-
Nat Aging
Targeting senescence induced by age or chemotherapy with a polyphenol-rich natural extract improves longevity and healthspan in mice. [Abstract]2024 Sep;4(9):1231-1248. PMID: 38951692
Isoquercitrin purchased from MedChemExpress. Usage Cited in: Nat Aging. 2024 Sep;4(9):1231-1248. [Abstract]
Quantification of SA-β-Gal assay of UV-B-irradiated IMR90 fibroblasts, treated with the indicated compounds at 1 μM concentration Isoquercetin.
-
Sci Adv
In situ protein corona-camouflaged supramolecular assemblies remodel thrombotic microenvironment for improved arterial homeostasis. [Abstract]2025 May 2;11(18):eadu6676. PMID: 40315315 -
Phytother Res
Isoquercitrin Promotes Angiogenesis Through the Genomic Signaling Pathway of the Estrogen Receptor-Alpha. [Abstract]2025 Oct;39(10):4802-4820. PMID: 40908639
Isoquercitrin purchased from MedChemExpress. Usage Cited in: Phytother Res. 2025 Oct;39(10):4802-4820. [Abstract]
Fluorescence image of ERα nuclear translocation by 100 nM Isoquercitrin (IQ). 17β-estradiol (E2,10 nM) serves as a positive control.
Isoquercitrin purchased from MedChemExpress. Usage Cited in: Phytother Res. 2025 Oct;39(10):4802-4820. [Abstract]
The mRNA expression of IGFBP4 and PGR was measured using RT-qPCR in EAhy926 KRR cells treated with 100 nM Isoquercitrin (IQ) or 10 nM E2.
Isoquercitrin purchased from MedChemExpress. Usage Cited in: Phytother Res. 2025 Oct;39(10):4802-4820. [Abstract]
Isoquercitrin (IQ) (50 mg/kg, i.p.) suppresses the protein expression of p-NF-κB, p-c-JUN, and p-p38 by western blot.
Isoquercitrin purchased from MedChemExpress. Usage Cited in: Phytother Res. 2025 Oct;39(10):4802-4820. [Abstract]
The mice were treated with 100 μg/kg E2 or 50 mg/kg Isoquercitrin (IQ) (i.p.) every day, the expression level of VEGFR2 in VEGFR2-Luc female mice was monitored by bioluminescent imaging.
-
Cell Rep
2023 Nov 10;42(11):113417. PMID: 37950872 -
-
Molecules
Roseoside Is a Bioactive Compound in Kirengeshoma koreana Nakai Extract with Potent In Vitro Antiviral Activity Against Hepatitis C Virus. [Abstract]2024 Oct 30;29(21):5130. PMID: 39519772 -
J Sep Sci
Oriented Immobilization Coupled With Ligand Fishing Strategy for Rapid Discovery of Direct HMGB1 Inhibitors in Taxus wallichiana var. mairei. [Abstract]2026 Apr;49(4):e70402. PMID: 41906428 -
Chem Biol Drug Des
Isoquercetin Ameliorates Osteoarthritis via Nrf2/NF-κB Axis: An In Vitro and In Vivo Study. [Abstract]2024 Sep;104(3):e14620. PMID: 39251394 -
Eur Rev Med Pharmacol Sci
Mulberry leaf extracts and quercetin glycosides promote glycogen accumulation in astrocytes. [Abstract]2025 Sep;29(9):425-433. PMID: 41059752
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (215.34 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (10.77 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL (10.77 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Protocol for Pharmacokinetic Study
Pharmacokinetic studies quantify how an organism handles a drug over time through absorption, distribution, metabolism, and excretion, and the core experimental readout is the concentration-time profile of parent drug and, when relevant, metabolites in biological matrices such as plasma, whole blood, urine, bile, or tissue. Pharmacokinetic analysis links dose, route, exposure, clearance, half-life, distribution, bioavailability, and systemic exposure to drug efficacy and toxicity hypotheses rather than measuring a signaling pathway directly. The literature links pharmacokinetics to drug-development phenotypes by showing that drug metabolism and pharmacokinetics influence compound progression, exposure-response interpretation, safety margins, dosing strategy, and failure risk during discovery and development. DMPK science contributes to compound optimization by integrating physicochemical properties, in vitro metabolism, transporter behavior, in vivo exposure, and pharmacodynamic contex
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Hepatotoxicity Study
This protocol evaluates hepatotoxicity using complementary in vivo mouse APAP acute liver injury and in vitro hepatocyte-based cytotoxicity readouts. In vivo APAP injury is assessed by serum ALT/AST, liver histology, hepatic glutathione, protein adducts, necrosis, inflammation, and regeneration-related endpoints. In vitro hepatotoxicity is assessed by loss of viability, leakage of ALT/AST/LDH, oxidative-stress markers, mitochondrial function, nuclear morphology, intracellular calcium, and high-content imaging endpoints.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
-
Data Sheet (281 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Lee S, et al. Relative protective activities of quercetin, quercetin-3-glucoside, and rutin in alcohol-induced liver injury. J Food Biochem. 2019 Aug 5:e13002. [Content Brief]
[2]. Tan C, et al. Modulation of nuclear factor-κB signaling and reduction of neural tube defects by quercetin-3-glucoside in embryos of diabetic mice. Am J Obstet Gynecol. 2018 Aug;219(2):197.e1-197.e8. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1534 mL | 10.7670 mL | 21.5341 mL | 53.8352 mL |
| 5 mM | 0.4307 mL | 2.1534 mL | 4.3068 mL | 10.7670 mL | |
| 10 mM | 0.2153 mL | 1.0767 mL | 2.1534 mL | 5.3835 mL | |
| 15 mM | 0.1436 mL | 0.7178 mL | 1.4356 mL | 3.5890 mL | |
| 20 mM | 0.1077 mL | 0.5384 mL | 1.0767 mL | 2.6918 mL | |
| 25 mM | 0.0861 mL | 0.4307 mL | 0.8614 mL | 2.1534 mL | |
| 30 mM | 0.0718 mL | 0.3589 mL | 0.7178 mL | 1.7945 mL | |
| 40 mM | 0.0538 mL | 0.2692 mL | 0.5384 mL | 1.3459 mL | |
| 50 mM | 0.0431 mL | 0.2153 mL | 0.4307 mL | 1.0767 mL | |
| 60 mM | 0.0359 mL | 0.1795 mL | 0.3589 mL | 0.8973 mL | |
| 80 mM | 0.0269 mL | 0.1346 mL | 0.2692 mL | 0.6729 mL | |
| 100 mM | 0.0215 mL | 0.1077 mL | 0.2153 mL | 0.5384 mL |